Compare IPST & ARTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPST | ARTL |
|---|---|---|
| Founded | 2011 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0M | 3.2M |
| IPO Year | 2024 | 2014 |
| Metric | IPST | ARTL |
|---|---|---|
| Price | $3.70 | $5.43 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 2 |
| Target Price | ★ $164.00 | N/A |
| AVG Volume (30 Days) | ★ 4.7M | 211.8K |
| Earning Date | 04-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,402,488.00 | N/A |
| Revenue This Year | $70.16 | N/A |
| Revenue Next Year | $60.33 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 5.41 | N/A |
| 52 Week Low | $0.24 | $0.52 |
| 52 Week High | $25.34 | $19.91 |
| Indicator | IPST | ARTL |
|---|---|---|
| Relative Strength Index (RSI) | 45.85 | 76.13 |
| Support Level | $2.75 | $0.93 |
| Resistance Level | $3.95 | $19.91 |
| Average True Range (ATR) | 0.96 | 0.39 |
| MACD | -0.41 | 0.39 |
| Stochastic Oscillator | 1.17 | 81.30 |
IP Strategy Holdings Inc operate a diversified business centered on digital asset-based infrastructure and intellectual property (IP) management, supplemented by a legacy craft spirits operating segment. The Company provides public market investors with broad exposure to the around $80 trillion programmable intellectual property economy in a regulated equity format. Its treasury reserve of $IP tokens provides direct participation in the Story ecosystem, which enables on-chain registration, licensing, and monetization of intellectual property.
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.